Quoting Vivek Subbiah, the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, on Twitter/X:
“Huge win for patients with RET+ thyroid cancers. Selpercatinib demonstrates Superior Progression-Free Survival Compared to Approved Multikinase Inhibitors in RET-Mutant Medullary Thyroid Cancer. Super thrilled and excited for all all RET+ patients globally. Knew that this baby would graduate with honors right from the 1st patient dosed.
Have you heard about Lazarus effect? Yes, this was the 1st ever RET+ Thyroid cancer patient dosed on the drug. Our clinic team witnessed 1st hand the power of precision medicine.
1. First RET+ patient story Annals of Oncology
sciencedirect.com/science/articl
2. NEJM paper
nejm.org/doi/pdf/10.105
3. Press release Loxo Oncology
investor.lilly.com/news-releases/
Source: Vivek Subbiah/Twitter